BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
Key Highlights
- ➤Two GLIX1 abstracts scheduled for presentation at the 31st SNO Annual Meeting
- ➤Preclinical research evaluates GLIX1 across multiple glioblastoma models
- ➤Phase 1/2a GLIX1 trial design presented for recurrent or progressive high-grade glioma
- ➤Phase 1/2a GLIX1 trial initiated in the first quarter of 2026
- ➤BioLineRx (BLRX) develops GLIX1 with Hemispherian collaboration
Expert Statements
Adam Robertson, Chief Scientific Officer, Hemispherian AS
“GLIX1, a TET2 activator targeting DNA damage response: potent anti-tumor activity across multiple glioblastoma models; orthotopic CDX models and a subcutaneous TMZ-resistant PDX model”
Ditte Primdahl, MD, Northwestern University Feinberg School of Medicine
“Phase 1/2a study of GLIX1, a novel first-in-class oral TET2 activator, for the treatment of recurrent or progressive high-grade glioma”
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day PR Newswire
TEL AVIV, Israel and OSLO, Norway, Oct. 8, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 will be presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day, taking place November 12-15 in Philadelphia, Pennsylvania.
Get started
Create a free account to read the full story.